Contribute Try STAT+ Today

Yesterday, I found out that I’m an “essential person” under Massachusetts’ new stay-at-home order. Should I update my LinkedIn? Greetings and welcome to another semi-regular column on the Covid-19 pandemic. In this edition: Past due for a coronavirus antibody test; the opportunity for convalescent plasma; shameless fund-raising stunts; a biotech buyside investor survey; and more dogs of biotech.

STAT reader Erik R. emails: “Have you heard anything concerning ADMA Biologics and their participation in convalescent plasma or IVIG for treatment of Covid-19?”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.